# Elliott Sigal > Elliott Sigal is a Series A investor at Amgen (Princeton) backing Health Care and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Amgen](https://shizune.co/investors/profile/amgen-2) - Location: Princeton, United States - Total investments: 2 - Lead investor: 0% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/elliott-sigal-aa978567/ Elliott Sigal is a Series A investor at Amgen in Princeton focused on Health Care and Biotechnology. Elliott Sigal, M.D., Ph.D. joined NEA as a Venture Partner and Senior Advisor in 2014. He is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was a principal architect of the successful Biopharma TransformationStrategy of the company. He has been instrumental in increasing R&D productivity, developing the company’s strategy in biologics and acquiring external innovation in Bristol’s String of Pearls initiative. Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology. In 2012, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence.Dr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. Dr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school he studied engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Dr. Sigal serves as a member of the Board of Directors for the Mead Johnson Nutrition Company and the Melanoma Research Alliance. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 2 | 100% | | Biotechnology | 2 | 100% | | Medical | 1 | 50% | | Life Science | 1 | 50% | | Therapeutics | 1 | 50% | ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 1 | 50% | | Series B | 1 | 50% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Mersana Therapeutics | Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts. | $35M | Series B | Mar 02, 2015 | | | Surface Oncology | Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to playvital roles in tumor immune-evasion. Surface is based in Cambridge, Mass. | $35M | Series A | Jan 08, 2015 | | 2 of 2 investments shown. ## Co-investors - [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 1 deal together - [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 1 deal together - [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 1 deal together - [Lilly Ventures](https://shizune.co/investors/profile/lilly-ventures) — VC Fund, 1 deal together - [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 1 deal together - [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 1 deal together ## About Amgen VC Fund · Thousand Oaks, United States Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases. The company is values-based and deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious diseases. They offer products for treating illness in the areas ofoncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. 5 contacts available at Amgen. | Name | Title | Profile | | --- | --- | --- | | Vance Coffman | Board of Director | https://shizune.co/investors/profile/vance-d-coffman | | Alexander Kamb | Senior Vice President, Discovery Research | https://shizune.co/investors/profile/alexander-kamb | | David Haddad | Director of Product Management | https://shizune.co/investors/profile/david-haddad-2 | | Elliott Sigal | Co-Chair, Scientific Advisory Board | https://shizune.co/investors/profile/elliott-sigal | | Esteban Santos | Executive Vice President, Operations | https://shizune.co/investors/profile/esteban-santos | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Elliott Sigal invest in? Elliott Sigal invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co